FDA warns US Stem Cell Clinic of significant deviations

The US regulatory body warned it will be stepping up enforcement actions against clinics that abuse the trust of patients or endanger their health with unsanitary conditions

The US Food and Drug Administration has posted a warning letter issued to US Stem Cell Clinic of Sunrise, Florida, and its Chief Scientific Officer Kristin Comella for marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice (GMP) requirements, including some that could impact the sterility of their products, putting patients at risk.

Stem cell clinics that mislead vulnerable patients into believing they are being given safe, effective treatments that are in full compliance with the law are dangerously exploiting consumers and putting their health at risk, said FDA Commissioner Scott Gottlieb.

As the FDA takes new steps to advance an efficient, modern approach to the regulation of cell based regenerative medicine, at the same time we will be stepping up our enforcement actions against clinics that abuse the trust of patients and, more important, endanger their health with unsanitary conditions or by purporting to have treatments which may not provide any benefit.

The FDA recently inspected US Stem Cell Clinic and found that it was processing adipose tissue (body fat) into stromal vascular fraction (stem cells derived from body fat) and administering the product both intravenously or directly into the spinal cord of patients to treat a variety of serious diseases or conditions.

The FDA has not reviewed or approved any biological products manufactured by US Stem Cell Clinic for any use.

During the inspection, FDA investigators also documented evidence of significant deviations from cGMP in the manufacture of at least 256 lots of stem cell products by the clinic. For example, the firm was cited for its failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of products purporting to be sterile, which puts patients at risk for infections.

US Stem Cell Clinic also tried to impede the FDAs investigation during the most recent inspection by refusing to allow entry except by appointment and by denying FDA investigators access to employees. Refusing to permit entry or FDA inspection is a violation of federal law.

The FDA has requested a response from US Stem Cell Clinic, including a statement of how the deviations noted in the warning letter will be corrected, within 15 working days. Companies that do not correct deviations risk additional enforcement action such as seizure, injunction, or prosecutions.

Companies